NASH - Articles and news items

BMS Phase II study in non-alcoholic steatohepatitis a success 

Industry news / 24 April 2017 / Niamh Marriott, Junior Editor

In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.

Novartis expands development programs for NASH with Allergan clinical partnership

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist…

FDA grants fast track for Shire’s NASH investigational treatment

FDA grants fast track for Shire’s NASH investigational treatment

Industry news / 29 July 2016 / Mandy Parrett, Editorial Assistant

Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+